Ashkan Emadi, Ph.D.
Affiliations: | 2004 | Illinois Institute of Technology, Chicago, IL, United States |
Area:
Organic Chemistry, Pharmaceutical ChemistryGoogle:
"Ashkan Emadi"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Kenneth W. Stagliano | grad student | 2004 | Illinois Institute of Technology | |
| (Regiocontrolled synthesis and HIV inhibitory properties of binaphthoquinone and trimeric naphthoquinone derivatives of conocurvone.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Uy GL, Aldoss I, Foster MC, et al. (2020) Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. Blood |
| Niyongere S, Sanchez-Petitto G, Masur J, et al. (2020) Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Pharmaceuticals (Basel, Switzerland). 13 |
| Patzke CL, Duffy AP, Duong VH, et al. (2020) Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine. 9 |
| Lee MH, Lapidus RG, Ferraris D, et al. (2019) Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics. Molecules (Basel, Switzerland). 24 |
| Adige S, Lapidus RG, Carter-Cooper BA, et al. (2019) Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. Cancer Chemotherapy and Pharmacology |
| Bukhari A, Dahiya S, Goloubeva O, et al. (2019) Pattern of Use and Outcomes with Donor Lymphocyte Infusion (DLI) and Unmanipulated Stem Cell Boost (SCB) after Allogeneic Hematopoietic Stem Cell Transplant (HSCT): A Single-Center Experience Biology of Blood and Marrow Transplantation. 25 |
| Singh ZN, Duong VH, Koka R, et al. (2018) High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen. Journal of Hematopathology. 11: 67-74 |
| Emadi A, Duong VH, Pantin J, et al. (2018) Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial Blood. 132: 332-332 |
| Sintim HO, Aman MJ, Holtsberg F, et al. (2018) KRX-101, a Novel FLT3 Inhibitor, Potently Active Against Resistant FLT3-ITD/FLT3-TKD Mutant AML in Vitro and In Vivo Blood. 132: 4049-4049 |
| Fathi AT, Blonquist TM, Emadi A, et al. (2018) Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia Blood. 132: 1431-1431 |